Randomized trial · people

ARA-290 improved small fiber neuropathy symptoms in sarcoidosis

Checked against the paper Randomized trialPublished by PepVault

The takeaway

This early, small human trial found ARA-290 well tolerated in sarcoidosis, with better neuropathy symptom scores than placebo but no edge on pain ratings.

Kind
Randomized trial
Studied in
People
Number studied
22
Published
2012
Journal
Mol Med

What they tested

The team tested whether ARA-290 is safe and eases symptoms of small fiber neuropathy (damage to the body's thinnest nerve fibers, often causing pain) in people with sarcoidosis.

How the study was done

A randomized, double-blind, placebo-controlled pilot trial in 22 patients with sarcoidosis, neuropathy and a pain score of at least 5. The trial gave 2 mg of ARA-290 (12 patients) or a placebo, a dummy treatment (10 patients), into a vein three times a week for 4 weeks.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

PepVault for iPhone

Taking ARA-290? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

Clinical exams and lab tests turned up no safety problems. At week 4, scores on the small fiber neuropathy screening list (SFNSL, a symptom questionnaire) fell by 11.5 points in the ARA-290 group, compared with 2.9 points on placebo, a significant difference (p < 0.05). The ARA-290 group also showed significant shifts from its own starting point in the pain and physical functioning parts of the SF-36, a quality-of-life survey (changes of -23.4 and -14.6). Pain intensity and fatigue scores got better by the same amount in both groups, and depression scores did not move.

What it doesn’t show

This was a small, 4-week pilot trial, and the quality-of-life changes were measured against each patient's starting point rather than against placebo. Pain and fatigue improved no more with ARA-290 than with placebo.

The paper

Heij et al. Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study. Mol Med. 2012.

The compound

More studies on ARA-290

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking ARA-290? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo